EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease

Yugendar R Alugubelli, Jing Xiao, Kaustav Khatua, Sathish Kumar, Long Sun iD, Yuying Ma, Xinyu R Ma iD, Veerabhadra R Vulupala, Sandeep Atla, Lauren R Blankenship, Demonta Coleman, Xuping Xie und 3 weitere

Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6495-6507

DOI: 10.1021/acs.jmedchem.3c02416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.04.2024. Verfasst von Yugendar R Alugubelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M Drug Discovery Center, Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Proteolysis, Coronavirus 3C Proteases. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIBIB NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have witnessed three coronavirus (CoV) outbreaks in the past two decades, including the COVID-19 pandemic caused by SARS-CoV-2. Main protease (MPro), a highly conserved protease among various CoVs, is essential for viral replication and pathogenesis, making it a prime target for antiviral drug development. Here, we leverage proteolysis targeting chimera (PROTAC) technology to develop a new class of small-molecule antivirals that induce the degradation of SARS-CoV-2 MPro. Among them, MPD2 was demonstrated to effectively reduce MPro protein levels in 293T cells, relying on a time-dependent, CRBN-mediated, and proteasome-driven mechanism. Furthermore, MPD2 exhibited remarkable efficacy in diminishing MPro protein levels in SARS-CoV-2-infected A549-ACE2 cells. MPD2 also displayed potent antiviral activity against various SARS-CoV-2 strains and exhibited enhanced potency against nirmatrelvir-resistant viruses. Overall, this proof-of-concept study highlights the potential of targeted protein degradation of MPro as an innovative approach for developing antivirals that could fight against drug-resistant viral variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsProteolysisCoronavirus 3C ProteasesHumansHEK293 CellsDrug DiscoveryCOVID-19 Drug TreatmentA549 Cells

Substanzen

Antiviral AgentsCoronavirus 3C Proteases

Autor:innen und Institutionen

  • Texas A&M Drug Discovery Center, Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
  • Department of Biology, Texas A&M University, College Station, Texas 77843, United States.
  • Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • Texas A&M Global Health Research Complex, Texas A&M University, College Station, Texas 77843, United States.
  • Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, United States.
  • Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, Texas 77030, United States.

ORCID-Profile: Long Sun, Xinyu R Ma, Benjamin W Neuman, Wenshe Ray Liu, Shiqing Xu

Förderung

  • NIAID NIH HHS
  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • Amon G. Carter Foundation
  • Welch Foundation
  • Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
  • Texas A and M University
  • National Institutes of Health

Zitieren

APA

Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Sun, L., Ma, Y., Ma, X. R., Vulupala, V. R., Atla, S., Blankenship, L. R., Coleman, D., Xie, X., Neuman, B. W., Liu, W. R., & Xu, S. (2024). Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry, 67(8), 6495-6507. https://doi.org/10.1021/acs.jmedchem.3c02416

Vancouver

Alugubelli YR, Xiao J, Khatua K, Kumar S, Sun L, Ma Y, et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry. 2024;67(8):6495-6507. doi:10.1021/acs.jmedchem.3c02416

BibTeX
@article{Alugubelli2024,
  author = {Alugubelli, Yugendar R and Xiao, Jing and Khatua, Kaustav and Kumar, Sathish and Sun, Long and Ma, Yuying and Ma, Xinyu R and Vulupala, Veerabhadra R and Atla, Sandeep and Blankenship, Lauren R and Coleman, Demonta and Xie, Xuping and Neuman, Benjamin W and Liu, Wenshe Ray and Xu, Shiqing},
  title = {Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {8},
  pages = {6495--6507},
  doi = {10.1021/acs.jmedchem.3c02416}
}
Kostenlos starten →